InflaRx (IFRX)
Develops C5a-pathway medicines centered on oral izicopan for inflammatory and renal diseases.
$2.02
vs last close−0.06 (−3.13%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 65.32% | 94.45M ADS | |
|---|---|---|---|
| 67 holders · as of Jun 30, 2026 | |||
| Insiders | 6.01% | 8.69M ADS | |
| 7 holders · as of Mar 18, 2026 | |||
| Strategic holders | 24.21% | 35.00M ADS | |
| 2 holders · as of May 12, 2026 | |||
| Other | 4.46% | 6.45M ADS | |
| remainder | |||
144.59M ADS (1 ADS = 1 ordinary shares) as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
67 holders · 94.45M shares · 29 new positions · 43 increased · 8 reduced · 3 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 22.93M | 15.86% | +15.00M | Aug 14, 2026 |
| TCG Crossover Management, LLC | 14.50M | 10.03% | +14.50Mnew | Aug 14, 2026 |
| FMR LLC | 8.16M | 5.65% | +8.16Mnew | Aug 13, 2026 |
| Commodore Capital LP | 7.30M | 5.05% | +7.30Mnew | Aug 14, 2026 |
| Spruce Street Capital LP | 5.35M | 3.70% | +5.35Mnew | Aug 13, 2026 |
| 683 Capital Management, LLC | 5.07M | 3.50% | +1.75M | Aug 14, 2026 |
| Farallon Capital Management LLC | 3.33M | 2.30% | +3.33Mnew | Aug 14, 2026 |
| Stempoint Capital LP | 3.23M | 2.23% | +3.23Mnew | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 11.70% | 7.93M | 13G | Feb 13, 2026 |
| TCG Crossover GP III, LLC | 9.80% | 14.50M | 13G | May 12, 2026 |
| Sirenia Capital Management LP | 6.10% | 8.91M | 13G | Aug 14, 2026 |
| Commodore Capital LP | 5.10% | 7.48M | 13G | Aug 17, 2026 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.